LOBEF (Lobe Sciences) EBIT per Share: $-0.02 (TTM As of Feb. 2026)


What is Lobe Sciences EBIT per Share?

Lobe Sciences LOBEF +10.34% EBIT per Share is $-0.02 as of Feb. 2026. The stock has 2 warning signs investors should review. Among 1,172 Biotechnology companies, Lobe Sciences ranks better than 74.83% on this metric.

Lobe Sciences's EBIT per Share for the three months ended in Feb. 2026 was $-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 was $-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was 35.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 40.90% per year. During the past 10 years, the average EBIT per Share Growth Rate was 12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Lobe Sciences's EBIT per Share or its related term are showing as below:

LOBEF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -76   Med: 26.9   Max: 55.7
Current: 35

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Lobe Sciences was 55.70% per year. The lowest was -76.00% per year. And the median was 26.90% per year.

LOBEF's 3-Year EBIT Growth Rate is ranked better than
74.83% of 1172 companies
in the Biotechnology industry
Industry Median: 15.35 vs LOBEF: 35.00

Lobe Sciences's EBIT for the three months ended in Feb. 2026 was $-1.74 Mil.

Lobe Sciences  (OTCPK:LOBEF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Lobe Sciences EBIT per Share Related Terms

Lobe Sciences EBIT per Share Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences EBIT per Share Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -0.25 -0.03 -0.03 -0.02

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.01 -0.00 -0.01

Lobe Sciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Lobe Sciences's EBIT per Share for the fiscal year that ended in Aug. 2025 is calculated as

EBIT per Share(A: Aug. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-3.091/138.720
=-0.02

Lobe Sciences's EBIT per Share for the quarter that ended in Feb. 2026 is calculated as

EBIT per Share(Q: Feb. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.737/269.487
=-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.02 mean?
Lobe Sciences (LOBEF) has a EBIT per Share of $-0.02 as of Feb. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lobe Sciences and its competitors. According to the industry distribution chart, Lobe Sciences ranks #295 out of 1172 companies in the Biotechnology industry, placing it in the top 25.2%.
Is Lobe Sciences' EBIT per Share too high?
Lobe Sciences' current EBIT per Share is $-0.02. Based on the distribution chart, Lobe Sciences ranks #295 out of 1172 companies in the Biotechnology industry, which is above the industry midpoint.
How does Lobe Sciences' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lobe Sciences ranks #295 out of 1172 companies for EBIT per Share. This puts Lobe Sciences in the upper half of its industry. The industry median EBIT per Share is 15.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lobe Sciences and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lobe Sciences's current EBIT per Share is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current EBIT per Share of $-0.02. The current EBIT per Share is $-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current EBIT per Share is $-0.02 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.